Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: MADHAVBAUG Hospital & Healthcare Services | Small Cap | Vaidya Sane Ayur Lab Share Price
BSE Share Price
Not Listed
Not Listed
Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: MADHAVBAUG Hospital & Healthcare Services | Small Cap | Vaidya Sane Ayur Lab Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹147 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹8.6
TTM Sales
₹107 Cr.
Book Value per Share
₹68.2
P/E Ratio
16.41
Lower than its 5-year historical median
Industry PE
92.5
Price to Book (P/B)
2.06
Lower than its 5-year historical median
Price to Sales (P/S)
1.38
Lower than its 5-year historical median
EV/EBITDA
8.34
Lower than its 5-year historical median
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
13.39%
Outperforms industry median
Return on Capital Employed (ROCE)
15.34%
In line with industry median
Return on Assets (ROA)
9.81%
Outperforms industry median
Operating Profit Margin
14.6%
Underperforms industry median
Net Profit Margin
8.41%
Underperforms industry median
Gross Profit Margin
15.8%
Underperforms industry median
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
14.36%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
8.12%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
25.73%
Asset Quality
Promoter Holding
66.34%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹61 Cr.
Equity
₹10.5 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00
Check Before You Invest
Quality
Not GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Weak
Is Vaidya Sane Ayurved Laboratories Ltd a good quality company?
Vaidya Sane Ayurved Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Vaidya Sane Ayurved Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Vaidya Sane Ayurved Laboratories Ltd vs industry peers?
Vaidya Sane Ayurved Laboratories Ltd revenue CAGR is 2.54%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Vaidya Sane Ayurved Laboratories Ltd?
Promoters hold 66.34% of the Vaidya Sane Ayurved Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Vaidya Sane Ayurved Laboratories Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of -22.22% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Vaidya Sane Ayurved Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 9% | 4.7% | 7.7% | 22.5% | 19.9% | 3.5% | 13.3% | 9.8% | - |
| Value Creation Index ⓘ | NA | NA | -0.4 | -0.7 | -0.5 | 0.6 | 0.4 | -0.8 | -0.1 | -0.3 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 62.5 | 75.2 | 52.3 | 74.7 | 99 | 97.3 | 87.1 | 99.6 | 100 |
| Sales YoY Gr. | - | NA | NA | 20.4% | -30.5% | 42.9% | 32.6% | -1.7% | -10.5% | 14.4% | - |
| Adj EPS ⓘ | 0 | 0 | 0.7 | -0.8 | 0.6 | 3.3 | 4.9 | 0.9 | 5.5 | 4.7 | 4.7 |
| YoY Gr. | - | NA | NA | -212.7% | NA | 489.3% | 49.7% | -82.6% | 534.9% | -14.5% | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 0 | 14 | 34.1 | 38.8 | 39.6 | 56.8 | 61.5 | 61.5 |
| Adj Net Profit ⓘ | 0 | 0 | 0.5 | -0.6 | 0.4 | 3.5 | 5.2 | 0.9 | 5.7 | 4.9 | 5 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 1.6 | 7.7 | 5.8 | -13.3 | -0.4 | 3.4 | 7.6 | 4.2 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 5.5 | 0.8 | 0.2 | -0.1 | -0.3 | 0.5 | 0.2 | 0.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 13.8% | 0.2% | 14.4% | ||||
| Adj EPS ⓘ | NA | 52.8% | -1.9% | -14.5% | ||||
| BVPSⓘ | NA | 34.4% | 16.6% | 8.3% | ||||
| Share Price | - | - | -22.2% | -48.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 5.7 | -6.6 | 4.4 | 15.2 | 13.5 | 1.9 | 10 | 7 | 7.6 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 5 | 3.9 | 6.3 | 9.8 | 9.1 | 3.3 | 12.6 | 10.5 | NAN |
| Net Profit Mgn % ⓘ | 0 | 0 | 0.8 | -0.7 | 0.8 | 4.6 | 5.2 | 0.9 | 6.6 | 4.9 | 5 |
| Debt to Equity ⓘ | 0 | 0 | 1 | 0.7 | 0.1 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 46 | 56 | 37 | 44 | 66 | 78 | 76 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | -26 | -45 | -34 | -24 | -19 | -23 | -13 | 0 |
Valuation of Vaidya Sane Ayur Lab - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|
| Sales | 99 | 99 | 90 | 107 |
| Operating Expenses ⓘ + | 91 | 95 | 76 | 91 |
| Operating Profit ⓘ | 9 | 5 | 14 | 16 |
| Operating Profit Margin (%) | 8.6% | 4.5% | 16.0% | 14.6% |
| Other Income ⓘ + | 1 | 2 | 2 | 2 |
| Interest ⓘ | 1 | 0 | 1 | 1 |
| Depreciation ⓘ | 3 | 3 | 4 | 6 |
| Profit Before Tax ⓘ | 6 | 3 | 10 | 11 |
| Tax ⓘ | 2 | 1 | 3 | 2 |
| Profit After Tax | 5 | 2 | 7 | 9 |
| PAT Margin (%) | 4.9% | 2.0% | 8.0% | 8.4% |
| Adjusted EPS (₹) | 4.6 | 1.9 | 6.8 | 8.6 |
| Dividend Payout Ratio (%) | 5.40% | 0% | 0% | 0% |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 40 | 42 | 63 | 72 | |||||||
| Debt + | 0 | 2 | 1 | 3 | |||||||
| Minority Interest | 0 | 0 | 0 | 0 | |||||||
| Trade Payables | 9 | 7 | 7 | 7 | |||||||
| Others Liabilities ⓘ | 5 | 19 | 8 | 24 | |||||||
| Total Liabilities ⓘ | 55 | 70 | 79 | 104 | |||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 21 | 28 | 34 | 34 | |||||||
| CWIP ⓘ | 2 | 2 | 1 | 2 | |||||||
| Investments ⓘ | 15 | 18 | 21 | 40 | |||||||
| Inventories | 3 | 4 | 4 | 4 | |||||||
| Trade Receivables | 6 | 6 | 7 | 10 | |||||||
| Cash Equivalents | 2 | 2 | 2 | 0 | |||||||
| Others Assets ⓘ | 6 | 8 | 9 | 13 | |||||||
| Total Assets ⓘ | 55 | 70 | 79 | 104 | |||||||
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | -1 | 25 | 5 |
| Cash Flow From Investing Activity ⓘ + | 1 | -13 | -24 | -24 |
| Cash Flow From Financing Activity ⓘ + | -1 | 15 | -1 | 17 |
| Net Cash Flow ⓘ | -1 | 1 | -0 | -2 |
| PARTICULARS | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 11.95 | 4.82 | 13.66 | 13.39 | ||||||
| ROCE (%) | 17.96 | 6.37 | 17.86 | 15.34 | ||||||
| Asset Turnover Ratio | 1.81 | 1.6 | 1.21 | 1.17 | ||||||
| PAT to CFO Conversion(x) | 0 | -0.5 | 3.57 | 0.56 | ||||||
| Working Capital Days | ||||||||||
| Receivable Days | 22.10 | 22.10 | 27.40 | 30.20 | ||||||
| Inventory Days | 12.60 | 13.80 | 16 | 12.60 | ||||||
| Payable Days | 118.50 | 114 | 145.80 | 143.30 | ||||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Annual reports
No annual reports available.
Concalls
No concalls available.
Vaidya Sane Ayurved Laboratories Ltd FAQs
The current trading price of Vaidya Sane Ayur Lab on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Vaidya Sane Ayur Lab stood at ₹147.4 Cr
The latest P/E ratio of Vaidya Sane Ayur Lab as of 31-Dec-1969 is 29.88.
The latest P/B ratio of Vaidya Sane Ayur Lab as of 31-Dec-1969 is 2.28.
The 52-week high of Vaidya Sane Ayur Lab is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vaidya Sane Ayur Lab is ₹99.62 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vaidya Sane Ayurved Laboratories Ltd is a below average quality company.
The key valuation ratios of Vaidya Sane Ayurved Laboratories Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vaidya Sane Ayurved Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Vaidya Sane Ayurved Laboratories Ltd
Vaidya Sane Ayurved Laboratories (Madhavbaug) is a unique medical service institution that strives to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda. The company’s approach to treatment using non-invasive, multidisciplinary and innovative therapies which has helped establish it as a dependable option for treating the chronic ailments. It is a health care provider primarily in the India’s chronic care ecosystem. It provides its healthcare services through Madhavbaug clinics. As on November 30, 2021, the company operates 274 clinics across Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Goa, Karnataka, Delhi and Chhattisgarh. Out of these 52 are company owned and 222 are franchise clinics. It also operates two cardiac prevention and rehabilitation hospitals in Khopoli and Nagpur respectively. Currently, the company’s network includes 274 Clinics and 2 Fully equipped Hospital.
At the company’s clinics and hospitals, it use modern diagnostics, diet and physiotherapy and advanced Ayurveda to provide Heart disease, Diabetes, Hypertension & Obesity reversal treatments to its patients. This helps in improving the exercise tolerance of patients - improvement in grade of symptoms, improvement in maximum oxygen uptake, reduction in Hba1c, and metabolic equivalents (METs).
Business area of the company
The company is a medical service institution engaged in the treatment of chronic ailments like cardiac disease, diabetes, hypertension, and obesity by combining modern technology with the traditional Ayurveda practices.
Major Events and Milestones
- 2006: First Cardiac Prevention and Rehabilitation Hospital at Khopoli and opening of first Madhavbaug Clinic at Dombivili, Maharashtra.
- 2009: Setting up of inhouse research and development team at Thane.
- 2012: First Cardiac Prevention and Rehabilitation Hospital at Nagpur.
- 2013: Opening of 100th Madhavbaug Clinic at Kankavli, Ratnagiri
- 2014: Arogyam Hriday Sampada launched with a Mission to create awareness of heart disease.
- 2015: Launch of therapies for risk factors such as Diabetes, Obesity and Hypertension at Madhavbaug Clinics.
- 2016: Disease wise diet kits introduced at Madhavbaug Clinics.
- 2016: Madhavbaug Institute of Preventive Cardiology established with MUHS.
- 2017: Entered into the state of Madhya Pradesh
- 2017: Madhavbaug Clinics received Frost and Sullivan’s 2017 India Best Practices Award.
- 2017: Randomised controlled trial by Madhavbaug published in Indian Heart Journal, Official publication of Cardiological Society of India.
- 2018: Madhavbaug Clinics enters in India Book of Records for Conducting GTT of 661 diabetic patients in single day at 13 different locations.
- 2018: Participated as main sponsor of World Ayurved Congress 2018 held at Ahmedabad.
- 2018: Opening of 200th Madhavbaug Clinic at Nanded, Maharashtra.
- 2018: Entered into the state of Uttar Pradesh and Gujarat.
- 2019: Entered into the state of Delhi.
- 2019: Madhavbaug introduced research based heart blockage management program.
- 2019: Achieved new registrations of over 90,000 patients and more than 27,000 stress tests conducted and over 3,00,000 panchkarma procedures performed.
- 2020: Launch of MIB Pulse Mobile Application for patient engagement.
- 2020: Entered into the state of Karnataka
- 2021: MIB Pulse Mobile Application achieved over 1,00,000 downloads.
- 2021: Opening of 250th Madhavbaug Clinic at Vashi.
- 2020: Entered into the state of Chhattisgarh.
- 2021: Research trial on one year follow-up of Diabetes patients treated by Madhavbaug published in Journal of Association of Physicians of India.
You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now